ArticleJournal of cancer research and clinical oncology2025
Brahmi (Bacopa monnieri) plant preparation facilitates to enhance the activities of dendritic cells to control non-small cell lung cancer (NSCLC).
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBrahmi (Bacopa monnieri) plant preparation (BPP) has been recognizedfor its immunomodulatory capabilities, but its molecular and epigenetic effects onimmune cells in non-small cell lung cancer (NSCLC) remain unknown.
objectiveThisstudy investigated the way BPP influenced the molecular phenotype and functionalprofile of monocyte-derived dendritic cells (DCs) derived from an NSCLC patient anda healthy donor.
resultBPP treatment enhanced DC maturation, as demonstrated byelevated levels of CD1d and co-stimulatory molecules (CD80/CD86), and conditionedsupernatants that efficiently activated autologous T cells. BPP increased proinflammatorysignaling molecules STAT1, STAT2, STAT4, and total NF-κB, whiledecreasing STAT3, STAT5, STAT6, and the DNA-repair protein DNAPKcs.Transcriptional analysis indicated a Th1-oriented immune program, characterized bythe up-regulation of TBX21, IFNG, and TP53, alongside the down-regulation ofGATA3, FOXP3, RORC, IL10, and MYC. Chromatin profiling revealed an enrichmentof H3K4me3 and H3K14ac, alongside p53 recruitment at the IFNG/TBX21 loci,accompanied by diminished levels of H3K27me3, HDAC2, and reduced promoteroccupancy by c-Myc and NF-κB. BPP enhanced the secretion of IFN-γ, IL-2, and TNF-α while diminishing IL-4, IL-10, and IL-17, establishing a pro-inflammatoryenvironment indicative of Th1-type polarization. Co-culture experiments validatedincreased cytotoxic T-cell activity against A549 cells (NSCLC cells), assessed throughLDH release and statistically confirmed via ANOVA with Tukey post-hoc analysis.
conclusionOverall, these findings demonstrate the ability of BPP to influence dendritic and T-cell responses in NSCLC via coordinated transcriptional and chromatinremodelling activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.